Johnson & Johnson announced the submission of two supplemental Biologics License Applications (sBLAs) to the FDA seeking approval of Tremfya (guselkumab) for the treatment of children 6 years… read more.
Johnson & Johnson announced the FDA approval of a supplemental New Drug Application (sNDA) for Spravato (esketamine) CIII nasal spray, making this innovative treatment the first and only… read more.
In recent years treatment with powerful biologic and targeted synthetic therapies has changed the landscape for arthritis, but currently finding the right treatment for each person is a… read more.
NICE (UK) 1.1Teclistamab is recommended as an option for treating relapsed and refractory multiple myeloma in adults, only after 3 or more lines of treatment (including an immunomodulatory… read more.
Johnson & Johnson announced more than 90 abstracts featuring data from the Company’s differentiated blood cancer portfolio and pipeline will be presented at the 66th American Society of Hematology (ASH)… read more.
Johnson & Johnson announced that the European Commission (EC) has approved Edurant (rilpivirine) for the treatment of HIV-1 infection in adults and children weighing at least 25 kg… read more.
Johnson & Johnson announced that treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate… read more.
Johnson & Johnson announced that 23 abstracts featuring new real-world and clinical trial data from across its neuropsychiatry portfolio and pipeline will be presented at the annual U.S…. read more.
Johnson & Johnson announced that 25 abstracts featuring robust research to understand unmet needs in generalized myasthenia gravis (gMG) and evaluate nipocalimab as a potential advanced treatment option… read more.
Janssen-Cilag International NV, a Johnson & Johnson company, announced the submission of a Type II variation application to the European Medicines Agency (EMA) seeking approval for an indication… read more.
Johnson & Johnson announced that the FDA has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC), a chronic disease of… read more.
Johnson & Johnson MedTech announced that DePuy Synthes, The Orthopaedics Company of Johnson & Johnson, has launched its TriLEAP Lower Extremity Anatomic Plating System, a comprehensive system with… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
